CCCC - C4 Therapeutics Inc

CCCC - C4 Therapeutics Inc

https://www.c4therapeutics.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

GlobeNewswire • 1 week, 4 days ago • score: 0.13

Development Candidate Targeting IRAK4 Now Progressing Toward Clinical Development Development Candidate Targeting IRAK4 Now Progressing Toward Clinical Development ...

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society ( IMS ) Annual Meeting

GlobeNewswire • 1 week, 5 days ago • score: 0.18

C4T to Host Webcast on September 20, 2025 at 3 pm ET C4T to Host Webcast on September 20, 2025 at 3 pm ET ...

C4 Therapeutics, Inc. ( CCCC ) Reports Q2 Loss, Misses Revenue Estimates

Zacks Commentary • 1 month, 1 week ago • score: 0.05

C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +2.63% and -0.57%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

C4 Therapeutics, Inc. ( CCCC ) Reports Q1 Loss, Tops Revenue Estimates

Zacks Commentary • 4 months, 1 week ago • score: 0.07

C4 Therapeutics (CCCC) delivered earnings and revenue surprises of 22.92% and 103.03%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

C4 Therapeutics ( CCCC ) Loses -21.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks Commentary • 6 months, 1 week ago • score: 0.17

C4 Therapeutics (CCCC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

C4 Therapeutics ( CCCC ) Loses -26.18% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks Commentary • 6 months, 2 weeks ago • score: 0.27

The heavy selling pressure might have exhausted for C4 Therapeutics (CCCC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

C4 Therapeutics, Inc. ( CCCC ) Reports Q4 Loss, Lags Revenue Estimates

Zacks Commentary • 6 months, 2 weeks ago • score: 0.12

C4 Therapeutics (CCCC) delivered earnings and revenue surprises of -11.36% and 39.45%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

C4 Therapeutics, Inc., a biopharmaceutical company, develops new therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. The company is headquartered in Watertown, Massachusetts.

52W High

$7.22

52W Low

$1.09

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

3.00

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.42

EV/Revenue (<3 favorable)

1.23

P/S (TTM) (<3 favorable)

5.65

P/B (<3 favorable)

1.11

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

9.75%

Institutions (25–75% balanced)

76.94%

Shares Outstanding

71,171,000

Float

50,030,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

34,240,000

Gross Profit (TTM)

-83,380,000

EPS (TTM)

-1.59

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-4.41%

ROE (TTM) (>15% strong)

-0.53%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.46

Momentum

Bearish momentum

Value

0.1149

Previous

0.1230

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025